RVL Pharmaceuticals plc Reports Second Quarter 2022 Financial Results; Provides Commercial Update
August 11, 2022 06:50 ET
|
RVL Pharmaceuticals plc
-- Second quarter 2022 UPNEEQ® net product sales of $8.4 million; 42% above first quarter -- -- Opportunity for cash runway to extend through 2023 following recently announced financings -- --...
RVL Pharmaceuticals plc Announces Insider and Athyrium-Led Financing
August 04, 2022 17:06 ET
|
RVL Pharmaceuticals plc
-- Secured $68.9 million in committed financing through a combination of equity and non-dilutive debt financing -- -- Cash runway anticipated to extend through 2023 with $43.9 million funded at...
RVL Pharmaceuticals plc to Discuss Second Quarter 2022 Financial Results and Provide Commercial Update
August 04, 2022 06:50 ET
|
RVL Pharmaceuticals plc
BRIDGEWATER, N.J., Aug. 04, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company focused on the commercialization of UPNEEQ®...
RVL Pharmaceuticals plc Announces Preliminary Second Quarter 2022 UPNEEQ® Net Product Sales Results
July 07, 2022 06:50 ET
|
RVL Pharmaceuticals plc
-- Expects second quarter 2022 preliminary UPNEEQ net product sales of approximately $8.4 million, representing an increase of 42% from the first quarter 2022 -- -- Second quarter 2022 net product...
RVL Pharmaceuticals plc Announces Result of Proposal 3 at Annual General Meeting
June 16, 2022 16:05 ET
|
RVL Pharmaceuticals plc
BRIDGEWATER, N.J., June 16, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced results of the Company’s...
RVL Pharmaceuticals plc to Present at Upcoming Conferences
May 16, 2022 06:50 ET
|
RVL Pharmaceuticals plc
BRIDGEWATER, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief...
RVL Pharmaceuticals plc Reports First Quarter 2022 Financial Results; Provides Commercial Update
May 12, 2022 06:50 ET
|
RVL Pharmaceuticals plc
First quarter 2022 UPNEEQ net product sales of $5.9 million; 90% growth over fourth quarter 2021 First quarter 2022 total revenues of $21.4 million, inclusive of $15.5 million from Santen License...
RVL Pharmaceuticals plc to Discuss First Quarter 2022 Financial Results and Provide Commercial Update
May 05, 2022 13:00 ET
|
RVL Pharmaceuticals plc
BRIDGEWATER, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced that the Company will release...
RVL Pharmaceuticals plc Announces Preliminary First Quarter 2022 UPNEEQ® Net Product Sales Results
April 06, 2022 06:50 ET
|
RVL Pharmaceuticals plc
-- Expects first quarter 2022 preliminary UPNEEQ net product sales of approximately $5.9 million, representing an increase of 90% from the fourth quarter 2021 -- -- Reaffirms fourth quarter 2022...
RVL Pharmaceuticals plc Reports Fourth Quarter and Full Year 2021 Financial Results; Provides Preliminary First Quarter 2022 UPNEEQ® Revenue Estimate and Business Update
March 30, 2022 16:05 ET
|
RVL Pharmaceuticals plc
Fourth quarter 2021 UPNEEQ product sales of $3.1 million, representing 39% growth over third quarter sales Fourth quarter and full year 2021 total revenues of $2.9 million and $17.5 million,...